FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137090744> ?p ?o ?g. }

• W3137090744 abstract "Abstract Background Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics. Significant intra- and inter-tumor heterogeneity and inadequate delivery of therapeutics across blood–brain barrier continue to be significant impediments towards developing therapies which can significantly enhance survival. We hypothesize that microRNAs have the potential to serve as effective therapeutics for glioblastoma as they modulate the activity of multiple signaling pathways, and hence can counteract heterogeneity if successfully delivered. Methods Using a computational approach, we identified microRNA-34a as a microRNA that maximally reduces the activation status of the three core signaling networks (the receptor tyrosine kinase, p53 and Rb networks) that have been found to be deregulated in most glioblastoma tumors. Glioblastoma cultures were transfected with microRNA-34a or control microRNA to assess biological function and therapeutic potential in vitro. Nanocells were derived from genetically modified bacteria and loaded with microRNA-34a for intravenous administration to orthotopic patient-derived glioblastoma xenografts in mice. Results Overexpression of microRNA-34a strongly reduced the activation status of the three core signaling networks. microRNA-34a transfection also inhibited the survival of multiple established glioblastoma cell lines, as well as primary patient-derived xenograft cultures representing the proneural, mesenchymal and classical subtypes. Transfection of microRNA-34a enhanced temozolomide (TMZ) response in in vitro cultures of glioblastoma cells with primary TMZ sensitivity, primary TMZ resistance and acquired TMZ resistance. Mechanistically, microRNA-34a downregulated multiple therapeutic resistance genes which are associated with worse survival in glioblastoma patients and are enriched in specific tumor spatial compartments. Importantly, intravenous administration of nanocells carrying miR-34a and targeted to epidermal growth factor receptor (EGFR) strongly enhanced TMZ sensitivity in an orthotopic patient-derived xenograft mouse model of glioblastoma. Conclusions Targeted bacterially-derived nanocells are an effective vehicle for the delivery of microRNA-34a to glioblastoma tumors. microRNA-34a inhibits survival and strongly sensitizes a wide range of glioblastoma cell cultures to TMZ, suggesting that combination therapy of TMZ with microRNA-34a loaded nanocells may serve as a novel therapeutic approach for the treatment of glioblastoma tumors." @default.
• W3137090744 created "2021-03-29" @default.
• W3137090744 creator A5015247761 @default.
• W3137090744 creator A5016790638 @default.
• W3137090744 creator A5022563151 @default.
• W3137090744 creator A5026033104 @default.
• W3137090744 creator A5047383083 @default.
• W3137090744 creator A5048782315 @default.
• W3137090744 creator A5060426932 @default.
• W3137090744 creator A5061950755 @default.
• W3137090744 creator A5070462994 @default.
• W3137090744 creator A5084780813 @default.
• W3137090744 creator A5087036316 @default.
• W3137090744 creator A5091652642 @default.
• W3137090744 date "2021-03-25" @default.
• W3137090744 modified "2023-10-16" @default.
• W3137090744 title "Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma" @default.
• W3137090744 cites W1121277736 @default.
• W3137090744 cites W1485770854 @default.
• W3137090744 cites W1609044025 @default.
• W3137090744 cites W1920052832 @default.
• W3137090744 cites W1966720603 @default.
• W3137090744 cites W1976970322 @default.
• W3137090744 cites W1983718760 @default.
• W3137090744 cites W1984424468 @default.
• W3137090744 cites W1989891384 @default.
• W3137090744 cites W1997950881 @default.
• W3137090744 cites W2011139878 @default.
• W3137090744 cites W2027542963 @default.
• W3137090744 cites W2030017878 @default.
• W3137090744 cites W2032735323 @default.
• W3137090744 cites W2036254354 @default.
• W3137090744 cites W2037647570 @default.
• W3137090744 cites W2040458067 @default.
• W3137090744 cites W2040827479 @default.
• W3137090744 cites W2047308202 @default.
• W3137090744 cites W2057851530 @default.
• W3137090744 cites W2070159291 @default.
• W3137090744 cites W2070765029 @default.
• W3137090744 cites W2079179944 @default.
• W3137090744 cites W2081113032 @default.
• W3137090744 cites W2082133979 @default.
• W3137090744 cites W2096024448 @default.
• W3137090744 cites W2096287682 @default.
• W3137090744 cites W2096439168 @default.
• W3137090744 cites W2105100844 @default.
• W3137090744 cites W2105711862 @default.
• W3137090744 cites W2106641840 @default.
• W3137090744 cites W2113039629 @default.
• W3137090744 cites W2133658633 @default.
• W3137090744 cites W2134659609 @default.
• W3137090744 cites W2139872110 @default.
• W3137090744 cites W2150371702 @default.
• W3137090744 cites W2161289668 @default.
• W3137090744 cites W2161845665 @default.
• W3137090744 cites W2175869408 @default.
• W3137090744 cites W2189897946 @default.
• W3137090744 cites W2335360019 @default.
• W3137090744 cites W2392045628 @default.
• W3137090744 cites W2410468716 @default.
• W3137090744 cites W2414952944 @default.
• W3137090744 cites W2415253563 @default.
• W3137090744 cites W2509715372 @default.
• W3137090744 cites W2554863679 @default.
• W3137090744 cites W2559588208 @default.
• W3137090744 cites W2564096649 @default.
• W3137090744 cites W2573318906 @default.
• W3137090744 cites W2585659713 @default.
• W3137090744 cites W2588025094 @default.
• W3137090744 cites W2588702485 @default.
• W3137090744 cites W2594392335 @default.
• W3137090744 cites W2603468422 @default.
• W3137090744 cites W2626315766 @default.
• W3137090744 cites W2739601826 @default.
• W3137090744 cites W2743981317 @default.
• W3137090744 cites W2760948530 @default.
• W3137090744 cites W2761941966 @default.
• W3137090744 cites W2762494548 @default.
• W3137090744 cites W2768632638 @default.
• W3137090744 cites W2802627587 @default.
• W3137090744 cites W2809035003 @default.
• W3137090744 cites W2913741278 @default.
• W3137090744 cites W2921638830 @default.
• W3137090744 cites W3011964824 @default.
• W3137090744 doi "https://doi.org/10.1186/s10020-021-00293-4" @default.
• W3137090744 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7993499" @default.
• W3137090744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33765907" @default.
• W3137090744 hasPublicationYear "2021" @default.
• W3137090744 type Work @default.
• W3137090744 sameAs 3137090744 @default.
• W3137090744 citedByCount "5" @default.
• W3137090744 countsByYear W31370907442021 @default.
• W3137090744 countsByYear W31370907442022 @default.
• W3137090744 countsByYear W31370907442023 @default.
• W3137090744 crossrefType "journal-article" @default.
• W3137090744 hasAuthorship W3137090744A5015247761 @default.
• W3137090744 hasAuthorship W3137090744A5016790638 @default.
• W3137090744 hasAuthorship W3137090744A5022563151 @default.
• W3137090744 hasAuthorship W3137090744A5026033104 @default.
• W3137090744 hasAuthorship W3137090744A5047383083 @default.

• next